标题
Onto better TRAILs for cancer treatment
作者
关键词
-
出版物
CELL DEATH AND DIFFERENTIATION
Volume 23, Issue 5, Pages 733-747
出版商
Springer Nature
发表日期
2016-03-04
DOI
10.1038/cdd.2015.174
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Cancer Cell-Autonomous TRAIL-R Signaling Promotes KRAS-Driven Cancer Progression, Invasion, and Metastasis
- (2015) Silvia von Karstedt et al. CANCER CELL
- Targeting disease by immunomodulation
- (2015) T Kaufmann et al. CELL DEATH AND DIFFERENTIATION
- Immunotherapy with liposome-bound TRAIL overcomes partial protection to soluble TRAIL-induced apoptosis offered by down-regulation of Bim in leukemic cells
- (2015) D. De Miguel et al. Clinical & Translational Oncology
- Inhalable self-assembled albumin nanoparticles for treating drug-resistant lung cancer
- (2015) Seong Ho Choi et al. JOURNAL OF CONTROLLED RELEASE
- Liposome-bound TRAIL induces superior DR5 clustering and enhanced DISC recruitment in histiocytic lymphoma U937 cells
- (2015) Diego De Miguel et al. LEUKEMIA RESEARCH
- C-type lectin-like molecule-1 (CLL1)-targeted TRAIL augments the tumoricidal activity of granulocytes and potentiates therapeutic antibody-dependent cell-mediated cytotoxicity
- (2015) Valerie R Wiersma et al. mAbs
- Enhancing the antitumor efficacy of a cell-surface death ligand by covalent membrane display
- (2015) Pradeep M. Nair et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Immuno-LipoTRAIL: Targeted Delivery of TRAIL-Functionalized Liposomal Nanoparticles
- (2014) Oliver Seifert et al. BIOCONJUGATE CHEMISTRY
- Apo2L/TRAIL and the Death Receptor 5 Agonist Antibody AMG 655 Cooperate to Promote Receptor Clustering and Antitumor Activity
- (2014) Jonathan D. Graves et al. CANCER CELL
- Getting TRAIL back on track for cancer therapy
- (2014) J Lemke et al. CELL DEATH AND DIFFERENTIATION
- sTRAIL coupled to liposomes improves its pharmacokinetic profile and overcomes neuroblastoma tumour resistance in combination with Bortezomib
- (2014) M. Loi et al. JOURNAL OF CONTROLLED RELEASE
- TRAIL-coated leukocytes that kill cancer cells in the circulation
- (2014) M. J. Mitchell et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- CD70-restricted specific activation of TRAILR1 or TRAILR2 using scFv-targeted TRAIL mutants
- (2014) J Trebing et al. Cell Death & Disease
- MAPK p38 and JNK have opposing activities on TRAIL-induced apoptosis activation in NSCLC H460 cells that involves RIP1 and caspase-8 and is mediated by Mcl-1
- (2013) Kaamar Azijli et al. APOPTOSIS
- Death receptors as targets in cancer
- (2013) O Micheau et al. BRITISH JOURNAL OF PHARMACOLOGY
- Selective CDK9 inhibition overcomes TRAIL resistance by concomitant suppression of cFlip and Mcl-1
- (2013) J Lemke et al. CELL DEATH AND DIFFERENTIATION
- Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer
- (2013) L Bracci et al. CELL DEATH AND DIFFERENTIATION
- A Phase 1B Study of Dulanermin in Combination With Modified FOLFOX6 Plus Bevacizumab in Patients With Metastatic Colorectal Cancer
- (2013) Zev A. Wainberg et al. Clinical Colorectal Cancer
- TRAIL-Based Therapeutic Approaches for the Treatment of Pediatric Malignancies
- (2013) C. Gasparini et al. CURRENT MEDICINAL CHEMISTRY
- Death receptor agonist therapies for cancer, which is the right TRAIL?
- (2013) Pamela M. Holland CYTOKINE & GROWTH FACTOR REVIEWS
- Tetravalent Antibody-scTRAIL Fusion Proteins with Improved Properties
- (2013) O. Seifert et al. MOLECULAR CANCER THERAPEUTICS
- APG350 Induces Superior Clustering of TRAIL Receptors and Shows Therapeutic Antitumor Efficacy Independent of Cross-Linking via Fc Receptors
- (2013) C. Gieffers et al. MOLECULAR CANCER THERAPEUTICS
- Liposomes Decorated with Apo2L/TRAIL Overcome Chemoresistance of Human Hematologic Tumor Cells
- (2013) Diego De Miguel et al. MOLECULAR PHARMACEUTICS
- Fn14•Trail Effectively Inhibits Hepatocellular Carcinoma Growth
- (2013) Alexandra Aronin et al. PLoS One
- CD40-directed scFv-TRAIL fusion proteins induce CD40-restricted tumor cell death and activate dendritic cells
- (2013) M El-Mesery et al. Cell Death & Disease
- Protective Roles for Caspase-8 and cFLIP in Adult Homeostasis
- (2013) Ricardo Weinlich et al. Cell Reports
- Development of liposomal formulations: From concept to clinical investigations
- (2013) Yuchen Fan et al. Asian Journal of Pharmaceutical Sciences
- The ‘complexities’ of life and death: Death receptor signalling platforms
- (2012) Laura S. Dickens et al. EXPERIMENTAL CELL RESEARCH
- Increased apoptosis induction in hepatocellular carcinoma by a novel tumor-targeted TRAIL fusion protein combined with bortezomib
- (2012) Kristin Wahl et al. HEPATOLOGY
- A sulfate polysaccharide/TNF-related apoptosis-inducing ligand (TRAIL) complex for the long-term delivery of TRAIL in poly(lactic-co-glycolic acid) (PLGA) microspheres
- (2012) Hyemin Kim et al. JOURNAL OF PHARMACY AND PHARMACOLOGY
- A Death Effector Domain Chain DISC Model Reveals a Crucial Role for Caspase-8 Chain Assembly in Mediating Apoptotic Cell Death
- (2012) Laura S. Dickens et al. MOLECULAR CELL
- Human Umbilical Cord Mesenchymal Stem Cells as Vehicles of CD20-Specific TRAIL Fusion Protein Delivery: A Double-Target Therapy against Non-Hodgkin’s Lymphoma
- (2012) Cihui Yan et al. MOLECULAR PHARMACEUTICS
- TRAIL conjugated to nanoparticles exhibits increased anti-tumor activities in glioma cells and glioma stem cells in vitro and in vivo
- (2012) Benny Perlstein et al. NEURO-ONCOLOGY
- On the TRAIL to successful cancer therapy? Predicting and counteracting resistance against TRAIL-based therapeutics
- (2012) L Y Dimberg et al. ONCOGENE
- Superior antitumoral activity of dimerized targeted single-chain TRAIL fusion proteins under retention of tumor selectivity
- (2012) M Siegemund et al. Cell Death & Disease
- The adaptor protein FADD and the initiator caspase-8 mediate activation of NF-κB by TRAIL
- (2012) M Grunert et al. Cell Death & Disease
- FLIPLinduces caspase 8 activity in the absence of interdomain caspase 8 cleavage and alters substrate specificity
- (2011) Cristina Pop et al. BIOCHEMICAL JOURNAL
- Proliferative versus apoptotic functions of caspase-8
- (2011) Bram J. van Raam et al. BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS
- PEGylated TNF-related apoptosis-inducing ligand (TRAIL) for effective tumor combination therapy
- (2011) Hai Hua Jiang et al. BIOMATERIALS
- Improved biological half-life and anti-tumor activity of TNF-related apoptosis-inducing ligand (TRAIL) using PEG-exposed nanoparticles
- (2011) Sung Mook Lim et al. BIOMATERIALS
- Doxorubicin-loaded human serum albumin nanoparticles surface-modified with TNF-related apoptosis-inducing ligand and transferrin for targeting multiple tumor types
- (2011) Sungho Bae et al. BIOMATERIALS
- An Fcγ Receptor-Dependent Mechanism Drives Antibody-Mediated Target-Receptor Signaling in Cancer Cells
- (2011) Nicholas S. Wilson et al. CANCER CELL
- Antibody-based fusion proteins to target death receptors in cancer
- (2011) Marco de Bruyn et al. CANCER LETTERS
- Cell Surface Delivery of TRAIL Strongly Augments the Tumoricidal Activity of T Cells
- (2011) M. de Bruyn et al. CLINICAL CANCER RESEARCH
- Randomized Phase II Study of Dulanermin in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Advanced Non–Small-Cell Lung Cancer
- (2011) Jean-Charles Soria et al. JOURNAL OF CLINICAL ONCOLOGY
- TRAIL and doxorubicin combination enhances anti-glioblastoma effect based on passive tumor targeting of liposomes
- (2011) Liangran Guo et al. JOURNAL OF CONTROLLED RELEASE
- cIAPs Block Ripoptosome Formation, a RIP1/Caspase-8 Containing Intracellular Cell Death Complex Differentially Regulated by cFLIP Isoforms
- (2011) Maria Feoktistova et al. MOLECULAR CELL
- A novel combination of TRAIL and doxorubicin enhances antitumor effect based on passive tumor-targeting of liposomes
- (2011) Liangran Guo et al. NANOTECHNOLOGY
- Catalytic activity of the caspase-8–FLIPL complex inhibits RIPK3-dependent necrosis
- (2011) Andrew Oberst et al. NATURE
- Rapid and efficient cancer cell killing mediated by high-affinity death receptor homotrimerizing TRAIL variants
- (2011) C R Reis et al. Cell Death & Disease
- Individual caspase-10 isoforms play distinct and opposing roles in the initiation of death receptor-mediated tumour cell apoptosis
- (2011) A Mühlethaler-Mottet et al. Cell Death & Disease
- Tumor delivery of macromolecular drugs based on the EPR effect
- (2010) Vladimir Torchilin ADVANCED DRUG DELIVERY REVIEWS
- The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect
- (2010) Jun Fang et al. ADVANCED DRUG DELIVERY REVIEWS
- Liposome-bound APO2L/TRAIL is an effective treatment in a rabbit model of rheumatoid arthritis
- (2010) Luis Martinez-Lostao et al. ARTHRITIS AND RHEUMATISM
- Superior serum half life of albumin tagged TNF ligands
- (2010) Nicole Müller et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Tumor-Selective Delivery of Macromolecular Drugs via the EPR Effect: Background and Future Prospects
- (2010) Hiroshi Maeda BIOCONJUGATE CHEMISTRY
- Tumor-targeted delivery of biologically active TRAIL protein
- (2010) H-Y Zhang et al. CANCER GENE THERAPY
- Chemotherapy overcomes TRAIL-R4-mediated TRAIL resistance at the DISC level
- (2010) A Morizot et al. CELL DEATH AND DIFFERENTIATION
- Oncogenic K-Ras Turns Death Receptors Into Metastasis-Promoting Receptors in Human and Mouse Colorectal Cancer Cells
- (2010) Frederik J.H. Hoogwater et al. GASTROENTEROLOGY
- Targeting AML through DR4 with a novel variant of rhTRAIL
- (2010) Eva Szegezdi et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- Phase 1b Study of Dulanermin (recombinant human Apo2L/TRAIL) in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Patients With Advanced Non-Squamous Non–Small-Cell Lung Cancer
- (2010) Jean-Charles Soria et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Dose-Escalation Study of Recombinant Human Apo2L/TRAIL, a Dual Proapoptotic Receptor Agonist, in Patients With Advanced Cancer
- (2010) Roy S. Herbst et al. JOURNAL OF CLINICAL ONCOLOGY
- PEGylated TNF-related apoptosis-inducing ligand (TRAIL)-loaded sustained release PLGA microspheres for enhanced stability and antitumor activity
- (2010) Tae Hyung Kim et al. JOURNAL OF CONTROLLED RELEASE
- TRAIL signaling is mediated by DR4 in pancreatic tumor cells despite the expression of functional DR5
- (2010) Johannes Lemke et al. JOURNAL OF MOLECULAR MEDICINE-JMM
- Preparation and Characterization of Apo2L/TNF-Related Apoptosis-Inducing Ligand–Loaded Human Serum Albumin Nanoparticles with Improved Stability and Tumor Distribution
- (2010) Tae Hyung Kim et al. JOURNAL OF PHARMACEUTICAL SCIENCES
- Melanoma-associated Chondroitin Sulfate Proteoglycan (MCSP)-targeted delivery of soluble TRAIL potently inhibits melanoma outgrowth in vitro and in vivo
- (2010) Marco de Bruyn et al. Molecular Cancer
- Improved Antitumor Activity and Tumor Targeting of NH2-Terminal-Specific PEGylated Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand
- (2010) S. Y. Chae et al. MOLECULAR CANCER THERAPEUTICS
- TRAIL treatment provokes mutations in surviving cells
- (2010) M M Lovric et al. ONCOGENE
- Potent antitumoral activity of TRAIL through generation of tumor-targeted single-chain fusion proteins
- (2010) B Schneider et al. Cell Death & Disease
- Fn14-TRAIL, a Chimeric Intercellular Signal Exchanger, Attenuates Experimental Autoimmune Encephalomyelitis
- (2009) Marjaneh Razmara et al. AMERICAN JOURNAL OF PATHOLOGY
- Is TRAIL the holy grail of cancer therapy?
- (2009) Thomas Newsom-Davis et al. APOPTOSIS
- Generation of new TRAIL mutants DR5-A and DR5-B with improved selectivity to death receptor 5
- (2009) Marine E. Gasparian et al. APOPTOSIS
- Gene delivery targeted to the brain using an Angiopep-conjugated polyethyleneglycol-modified polyamidoamine dendrimer
- (2009) Weilun Ke et al. BIOMATERIALS
- Cullin3-Based Polyubiquitination and p62-Dependent Aggregation of Caspase-8 Mediate Extrinsic Apoptosis Signaling
- (2009) Zhaoyu Jin et al. CELL
- Targeted Cancer Immunotherapy Using Ligands of the Tumor Necrosis Factor Super-Family
- (2009) E. Bremer et al. CURRENT DRUG TARGETS
- Connective Tissue-Activating Peptide III: A Novel Blood Biomarker for Early Lung Cancer Detection
- (2009) John Yee et al. JOURNAL OF CLINICAL ONCOLOGY
- Trimer Stabilization, Oligomerization, and Antibody-Mediated Cell Surface Immobilization Improve the Activity of Soluble Trimers of CD27L, CD40L, 41BBL, and Glucocorticoid-Induced TNF Receptor Ligand
- (2009) A. Wyzgol et al. JOURNAL OF IMMUNOLOGY
- A novel AML-selective TRAIL fusion protein that is superior to Gemtuzumab Ozogamicin in terms of in vitro selectivity, activity and stability
- (2009) B ten Cate et al. LEUKEMIA
- TRAILing death in cancer
- (2009) Gregory Mellier et al. MOLECULAR ASPECTS OF MEDICINE
- Engineering a leucine zipper-TRAIL homotrimer with improved cytotoxicity in tumor cells
- (2009) D. V. Rozanov et al. MOLECULAR CANCER THERAPEUTICS
- The Fas–FADD death domain complex structure unravels signalling by receptor clustering
- (2009) Fiona L. Scott et al. NATURE
- XIAP discriminates between type I and type II FAS-induced apoptosis
- (2009) Philipp J. Jost et al. NATURE
- Membrane-bound Fas ligand only is essential for Fas-induced apoptosis
- (2009) Lorraine A. O’ Reilly et al. NATURE
- Cooperation between Apo2L/TRAIL and bortezomib in multiple myeloma apoptosis
- (2008) Patricia Balsas et al. BIOCHEMICAL PHARMACOLOGY
- TRAIL and cancer therapy
- (2008) Frank A.E. Kruyt CANCER LETTERS
- TRAIL receptor signalling and modulation: Are we on the right TRAIL?
- (2008) Devalingam Mahalingam et al. CANCER TREATMENT REVIEWS
- Structural and functional analysis of the interaction between the agonistic monoclonal antibody Apomab and the proapoptotic receptor DR5
- (2008) C Adams et al. CELL DEATH AND DIFFERENTIATION
- Tumor resistance to specific lysis: A major hurdle for successful immunotherapy of cancer
- (2008) Salem Chouaib et al. CLINICAL IMMUNOLOGY
- TRAIL receptor-targeted therapeutics: Resistance mechanisms and strategies to avoid them
- (2008) A THORBURN et al. DRUG RESISTANCE UPDATES
- Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect
- (2008) H. Maeda et al. EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS
- Resistance of Tumor Cells to Cytolytic T Lymphocytes Involves Rho-GTPases and Focal Adhesion Kinase Activation
- (2008) Soraya Abouzahr-Rifai et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- DR4-selective Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL) Variants Obtained by Structure-based Design
- (2008) Vicente Tur et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Targeted delivery of a designed sTRAIL mutant results in superior apoptotic activity towards EGFR-positive tumor cells
- (2008) Edwin Bremer et al. JOURNAL OF MOLECULAR MEDICINE-JMM
- Enhancement of antitumor properties of TRAIL by targeted delivery to the tumor neovasculature
- (2008) L. Cao et al. MOLECULAR CANCER THERAPEUTICS
- Potent Systemic Anticancer Activity of Adenovirally Expressed EGFR-Selective TRAIL Fusion Protein
- (2008) Edwin Bremer et al. MOLECULAR THERAPY
- Nanoparticle therapeutics: an emerging treatment modality for cancer
- (2008) Mark E. Davis et al. NATURE REVIEWS DRUG DISCOVERY
- The TWEAK–Fn14 cytokine–receptor axis: discovery, biology and therapeutic targeting
- (2008) Jeffrey A. Winkles NATURE REVIEWS DRUG DISCOVERY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now